Imaging Diagnosis of Primary Liver Cancer Using Magnetic Resonance Dilated Weighted Imaging and the Treatment Effect of Sorafenib

Abstract

Objective. This work explores the application value of dilated weighted imaging (DWI) in the diagnosis of primary liver cancer (PLC) and the effect of sorafenib in the treatment of PLC. Methods. 88 patients with PLC who were treated in The First Affiliated Hospital of Northwest University from March 2019 to March 2021 were selected and randomly rolled into an experimental group and a control group, with 44 cases in each group. Patients in both groups were treated with transcatheter arterial chemoembolization (TACE), and the patients in the experimental group were treated with oral sorafenib on the basis of TACE. The indicators of complications, short-term efficacy (STE), and long-term efficacy (LTE) of the two groups were observed. All patients received DWI and magnetic resonance (MR) plain scan. The diagnostic accuracy and misdiagnosis rate of the two methods in diagnosing the PLC were compared. Results. The accuracy, specificity, and sensitivity of MR plain scan were 68%, 88%, and 89%, respectively, while those of DWI were 96%, 95%, and 94.2%, respectively. It indicated that the accuracy, specificity, and sensitivity of DWI in diagnosing lesions were better than those of MR plain scan, especially the diagnostic accuracy ( P < 0.05 ). The objective response rate (ORR) and disease control rate (DCR) of the STE in the experimental group were 30% and 97%, respectively, and those in the control group were 6% and 54.5%, respectively. The experimental group’s mean progression-free survival (mPFS) and mean overall survival (mOS) were 12 and 25 months, respectively, while the control group’s were 8 and 19 months, respectively. It was concluded that the mPFS and mOS of patients receiving TACE combined with oral sorafenib were much higher than those receiving TACE only ( P < 0.05 ). Conclusion. DWI and TACE combined with sorafenib had high application value in the diagnosis and treatment of PLC.

Comparison of Clinical Efficacy of Molecular Targeted Drugs Combined with Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemoembolization Alone for Primary Liver Cancer

“…It is often adopted in the adjuvant treatment of advanced LC [29]. It was con rmed that sorafenib is valid and safe in advanced LC [30,31]. Bevacizumab monotherapy is effective in the treatment of LC, and the results of bevacizumab combined with chemotherapy drugs or other molecular targeted therapy drugs are encouraging.…”